FDA Vaccines Advisory Committee Meets on Moderna’s mRNA Influenza Vaccine MFLUSIVA

The FDA Vaccines and Related Biological Products Advisory Committee holds a meeting at 8:30 a.m. ET on June 18 to discuss and make recommendations on the safety and effectiveness of MFLUSIVA (Influenza Vaccine, mRNA), manufactured by Moderna TX Inc., with a requested indication in Biologics License Application STN 125869/0 for the prevention of influenza disease caused by influenza virus subtypes A and B represented in the vaccine, in persons 50 years of age and older.